Precision Biosciences (DTIL) EBITDA (2018 - 2026)
Precision Biosciences (DTIL) reported EBITDA of -$9.1 million for Q1 2026, up 58.96% year-over-year from -$5.7 million in Q1 2025, and down 172.55% on a QoQ basis from $12.5 million in Q4 2025.
Precision Biosciences (DTIL) has 9 years of EBITDA data on file, last reported at -$9.1 million in Q1 2026.
- Quarterly EBITDA rose 58.96% year-over-year to -$9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$39.1 million (up 11.29% YoY) and the FY2025 annual result came in at -$52.1 million, down 99.33% from the prior year.
- EBITDA retreated to -$9.1 million in Q1 2026 per DTIL's latest filing, from $12.5 million in the prior quarter.
- Across five years, EBITDA topped out at $24.1 million in Q2 2024 and bottomed at -$29.6 million in Q2 2022.
- The 5-year median for EBITDA is -$14.7 million (2022), against an average of -$12.6 million.
- The widest annual swing landed in 2024, when EBITDA soared 871.68%; it then slumped 428.11% in 2025.
- Tracing DTIL's EBITDA over 5 years: stood at -$12.1 million in 2022, then fell by 22.97% to -$14.9 million in 2023, then tumbled by 66.86% to -$24.8 million in 2024, then jumped by 150.34% to $12.5 million in 2025, then sank by 172.55% to -$9.1 million in 2026.
- Per Business Quant, the three latest DTIL EBITDA figures stand at -$9.1 million (Q1 2026), $12.5 million (Q4 2025), and -$20.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Precision Biosciences | 171.70 Mn | 70.52 Mn | - | -9.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.08 Mn |
| Dec 31, 2025 | 12.51 Mn |
| Sep 30, 2025 | -20.67 Mn |
| Jun 30, 2025 | -21.88 Mn |
| Mar 31, 2025 | -22.11 Mn |
| Dec 31, 2024 | -24.85 Mn |
| Sep 30, 2024 | -21.28 Mn |
| Jun 30, 2024 | 24.15 Mn |
| Mar 31, 2024 | -4.19 Mn |
| Dec 31, 2023 | -14.89 Mn |
| Sep 30, 2023 | -12.36 Mn |
| Jun 30, 2023 | -3.13 Mn |
| Mar 31, 2023 | -13.35 Mn |
| Dec 31, 2022 | -12.11 Mn |
| Sep 30, 2022 | -14.68 Mn |
| Jun 30, 2022 | -29.55 Mn |
| Mar 31, 2022 | -27.34 Mn |
| Dec 31, 2021 | -30.72 Mn |
| Sep 30, 2021 | -11.54 Mn |
| Jun 30, 2021 | 21.63 Mn |
| Mar 31, 2021 | -18.74 Mn |
| Dec 31, 2020 | -23.48 Mn |
| Sep 30, 2020 | -26.04 Mn |
| Jun 30, 2020 | -32.81 Mn |
| Mar 31, 2020 | -27.50 Mn |
| Dec 31, 2019 | -21.86 Mn |
| Sep 30, 2019 | -21.98 Mn |
| Jun 30, 2019 | -23.87 Mn |
| Mar 31, 2019 | -19.49 Mn |
| Dec 31, 2018 | -16.11 Mn |
| Sep 30, 2018 | -10.45 Mn |
| Jun 30, 2018 | -12.13 Mn |
| Mar 31, 2018 | -9.24 Mn |